These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28799326)

  • 1. Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life.
    Bukrinski JT; Sønderby P; Antunes F; Andersen B; Schmidt EGW; Peters GHJ; Harris P
    Biochemistry; 2017 Sep; 56(36):4860-4870. PubMed ID: 28799326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin-binding domain extends half-life of glucagon-like peptide-1.
    Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
    Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin.
    Yang B; Kim JC; Seong J; Tae G; Kwon I
    Biomater Sci; 2018 Jul; 6(8):2092-2100. PubMed ID: 29881837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface.
    Schmidt MM; Townson SA; Andreucci AJ; King BM; Schirmer EB; Murillo AJ; Dombrowski C; Tisdale AW; Lowden PA; Masci AL; Kovalchin JT; Erbe DV; Wittrup KD; Furfine ES; Barnes TM
    Structure; 2013 Nov; 21(11):1966-78. PubMed ID: 24120761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FcRn binding properties of an abnormal truncated analbuminemic albumin variant.
    Andersen JT; Daba MB; Sandlie I
    Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.
    Andersen JT; Cameron J; Plumridge A; Evans L; Sleep D; Sandlie I
    J Biol Chem; 2013 Aug; 288(33):24277-85. PubMed ID: 23818524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein.
    Yang B; Kwon I
    Mol Pharm; 2021 Jun; 18(6):2397-2405. PubMed ID: 33983743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
    Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human serum albumin presents isoform variants with altered neonatal Fc receptor interactions.
    Leblanc Y; Berger M; Seifert A; Bihoreau N; Chevreux G
    Protein Sci; 2019 Nov; 28(11):1982-1992. PubMed ID: 31583777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation.
    Schelde KK; Nicholls K; Dagnæs-Hansen F; Bunting K; Rawsthorne H; Andersen B; Finnis CJA; Williamson M; Cameron J; Howard KA
    J Biol Chem; 2019 Mar; 294(10):3735-3743. PubMed ID: 30602565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
    Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
    MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn).
    Sand KM; Bern M; Nilsen J; Dalhus B; Gunnarsen KS; Cameron J; Grevys A; Bunting K; Sandlie I; Andersen JT
    J Biol Chem; 2014 Dec; 289(50):34583-94. PubMed ID: 25344603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
    Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
    J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
    Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
    MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants.
    Petersen SS; Kläning E; Ebbesen MF; Andersen B; Cameron J; Sørensen ES; Howard KA
    Mol Pharm; 2016 Feb; 13(2):677-82. PubMed ID: 26654692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights into neonatal Fc receptor-based recycling mechanisms.
    Oganesyan V; Damschroder MM; Cook KE; Li Q; Gao C; Wu H; Dall'Acqua WF
    J Biol Chem; 2014 Mar; 289(11):7812-24. PubMed ID: 24469444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs.
    Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA
    J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo.
    Qiu Y; Lv W; Xu M; Xu Y
    J Control Release; 2016 May; 229():37-47. PubMed ID: 26988600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.